Education
About Us
Working with TipRanks
Follow Us
BetterLife Pharma (TSE:BETR)
:BETR
BETR Stock Chart & Stats
C$0.04
C$0.01(9.52%)
At close: 4:00 PM EST
C$0.04
C$0.01(9.52%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.12
Previous CloseN/A
Volume50.00
Average Volume (3M)121.96K
Market Cap
C$10.63M
Enterprise ValueC$13.56M
Total Cash (Recent Filing)C$7.96K
Total Debt (Recent Filing)C$659.63K
Price to Earnings (P/E)―
Beta-0.34
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding151,896,680
10 Day Avg. Volume118,740
30 Day Avg. Volume121,961
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)-1.51
Price to Sales (P/S)0.00
P/FCF Ratio-7.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnOperating cash outflow has narrowed materially, indicating the company reduced discretionary spending or optimized operations. This durable reduction extends runway and lowers near-term financing pressure, improving odds of advancing clinical programs over the next several quarters.
Narrowing Net LossesConsistent year-over-year reduction in net losses suggests improving operational efficiency and tighter cost control. Over a 2–6 month horizon this trend supports sustainability of R&D activity without proportionate increases in external funding, reducing dilution risk if maintained.
Focused Therapeutic StrategyA clear focus on mental health and neurology targets large, structural unmet needs and established regulatory pathways. This concentration helps prioritize R&D spend, attract targeted partnerships or grants, and supports durable strategic positioning versus unfocused early-stage peers.
Bears Say
No RevenueAbsence of product revenue means the business remains fully pre-revenue and dependent on financing for operations. That limits visibility into commercial viability and means sustaining R&D and development timelines requires continued capital access over many quarters.
Negative Shareholders' EquityMaterial negative equity and minimal tangible assets constrain financial flexibility and increase restructuring or dilution risk. Over a multi-quarter horizon, this weak capital structure narrows strategic options and heightens dependence on external funding or partnerships to continue operations.
Ongoing Negative Free Cash FlowDespite improved burn, free cash flow remains negative, signaling persistent funding needs to support R&D and corporate costs. This structural cash shortfall implies recurring financing requirements that can dilute shareholders or delay programs if capital access tightens over the next several quarters.
BetterLife Pharma News
BETR FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was C$0.04 and its highest was C$0.12 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is C$10.63M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Jun 02, 2026 which is in 86 days.
How were BetterLife Pharma’s earnings last quarter?
BetterLife Pharma released its earnings results on Dec 19, 2025. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 151,896,680 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
BetterLife Pharma reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in TSE:BETR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---